Regional prostate cancer means the cancer has spread beyond the prostate itself but remains confined to nearby structures, most commonly the pelvic lymph nodes. It sits between localized cancer (still inside the prostate) and distant cancer (spread to bones or organs far from the pelvis). The 5-year relative survival rate for regional prostate cancer is greater than 99%, based on data from men diagnosed between 2015 and 2021.
What “Regional” Actually Means
Cancer registries, including the National Cancer Institute’s SEER program, sort prostate cancer into three summary stages: localized, regional, and distant. Regional prostate cancer covers two scenarios. In one, the tumor has grown through the prostate’s outer capsule and into adjacent tissue, such as the seminal vesicles or the bladder neck. In the other, cancer cells have reached nearby lymph nodes in the pelvis but have not traveled to distant parts of the body.
The pelvic lymph nodes most frequently affected are the external and internal iliac nodes, followed by the obturator, common iliac, and presacral nodes. All of these sit within the pelvis, relatively close to the prostate. Once cancer reaches lymph nodes outside the pelvis, like those along the aorta in the abdomen, it is reclassified as distant rather than regional.
How It Fits Into Formal Staging
The TNM system, which doctors use for detailed staging, maps onto the SEER summary stages. Regional prostate cancer typically corresponds to Stage III or Stage IVA. Stage III includes tumors that have extended beyond the prostate capsule or invaded the seminal vesicles but have not reached lymph nodes. Stage IVA specifically describes cancer that has spread to regional lymph nodes (classified as N1) but shows no distant metastases (M0).
That Stage IV label can be alarming, but the distinction between IVA and IVB matters enormously. Stage IVA, with only regional lymph node involvement, carries a far better prognosis than Stage IVB, where cancer has spread to bones or distant organs.
How Regional Disease Is Detected
Traditional imaging tools like CT scans and standard MRI have historically struggled to identify small deposits of cancer in pelvic lymph nodes. CT correctly identifies pelvic lymph node involvement only about 26% of the time, and MRI catches roughly 45% of cases. A newer type of scan, PSMA PET/CT, has dramatically improved detection. This scan targets a protein found on the surface of prostate cancer cells and identifies pelvic lymph node spread with about 87% sensitivity and 92% overall accuracy.
PSMA PET scans have changed how many men are staged. Some cancers previously thought to be localized are now correctly identified as regional before treatment begins, which allows for more precise treatment planning.
How Tumor Grade Affects the Picture
Not all regional prostate cancers behave the same way. The Gleason score, which grades how abnormal cancer cells look under a microscope, plays a major role in prognosis. Scores range from 6 (the least aggressive pattern typically diagnosed) to 10 (the most aggressive). These scores are now grouped into Grade Groups 1 through 5 for simplicity.
Higher-grade tumors, those in Grade Group 4 (Gleason 8) or Grade Group 5 (Gleason 9 or 10), are more likely to have already spread at the time of diagnosis and tend to be harder to control long term. A man with regional disease and a Gleason 6 faces a very different situation than someone with regional disease and a Gleason 9, even though both fall under the same staging category. Prognosis for regional prostate cancer is greatly affected by whether lymph nodes are involved and, if so, how aggressive the cancer cells appear.
Treatment for Regional Prostate Cancer
Treatment for regional disease is more intensive than for early-stage prostate cancer but remains curative in intent. The main options include radiation therapy, surgery to remove the prostate (radical prostatectomy), and hormone therapy that lowers testosterone levels to slow cancer growth. Most men with regional disease receive a combination of these rather than a single approach.
Radiation combined with hormone therapy is one of the most common strategies. The hormone therapy, which suppresses testosterone, typically begins before or alongside radiation. A recent meta-analysis found that the benefits of hormone therapy improve in a nonlinear fashion with longer duration, but the gains tend to plateau beyond 9 to 12 months depending on the specific risk profile. For men with high-risk or very high-risk features, longer courses are often used.
Surgery is also an option for some men with regional disease, particularly when lymph node involvement is limited. Surgeons often remove pelvic lymph nodes during the procedure to evaluate how far the cancer has spread. If cancer is found in removed nodes, additional treatment with radiation or hormone therapy may follow.
What the Survival Numbers Mean
The greater than 99% five-year relative survival rate for regional prostate cancer is encouraging, but it deserves context. “Relative survival” compares men with this diagnosis to men of the same age in the general population. It does not mean the cancer is guaranteed not to return. Some regional cancers recur after initial treatment, requiring additional rounds of therapy.
Long-term outcomes depend on several factors working together: the Gleason grade, PSA levels at diagnosis, the number of lymph nodes involved, and how completely the cancer responds to initial treatment. Men with a single positive lymph node and a lower Gleason score generally do better than those with multiple positive nodes and high-grade disease. Your doctor will use all of these variables together, not just the stage alone, to estimate your individual outlook and recommend a treatment plan.